Mirvete Rama^1*, Mirela Miraci², Idriz Balla³, Ela Petrela⁴, Ledjan Malaj², Anjeza Koleci<sup>5

1</sup>Pharmaceutical Service “Mother Teresa” Hospital, Tirana, Albania; ²Medicine University, Faculty of Pharmacy, Tirana, Albania; ³University Hospital Center “Mother Theresa”, Tirana, Albania; ⁴Medicine University, Public Health Faculty, Tirana, Albania; ⁵Bayer Representation Office, Tirana, Albania


 

AIM: The study aim is to evaluate the cost-effectiveness of thrombolytic treatment in acute MI comparing with anticoagulants therapy and between each other thrombolytic (SK, r-Pa).

MATERIAL AND METHODS: We used a prospective registry of all patients admitted for acute myocardial infarction in intensive care units in Tirana. The average drugs cost was calculated for the hospitalization period in Albanian money (ALL). Survival and life quality were estimated by phone contact 1 year after acute MI.

RESULTS: Anticoagulant group cost is 23865.3 ALL (170.5€), SK group cost is 54148.63 ALL (386.7€), r-Pa group has a cost of 92184.90 ALL (658.5€). In the group treated with SK the hospital survival is 100%, while in the control group 88.8%. Reteplase group has a lower period of stay in hospital than SK group 13.04 days vs. 17.97 days, mean age in group treated with r-Pa is 64.29 ± 10.03 approximate with anticoagulant group mean age 64.17 ± 11.08; differ significantly with SK group mean age 56.75 ± 10.04. Survival after 1 year was 96.4% for r-Pa and 96.9% SK.

CONCLUSIONS: SK and r-Pa are successful thrombolytics with high effectiveness. It is gained a higher survival with the thrombolytic treatments. Reteplase is well tolerated in older patients than SK, is easier to apply than Streptokinase, but has higher cost.
 

..................

Citation: Rama M, Miraci M, Balla I, Petrela E, Malaj L, Koleci A. Cost-Effectiveness of Thrombolytic Therapy, Compared with Anticoagulants Therapy in the Treatment of Acute Myocardial Infarction in Albania. OA Maced J Med Sci. http://dx.doi.org/10.3889/oamjms.2015.060
Key words: Acute Myocardial Infarction; Cost-effectiveness; Thrombolytics; Streptokinase (SK); Reteplase(r-Pa); anticoagulants.
*Correspondence: Mrs. Mirvete Rama. "Mother Theresa" Hospital, Pharmacy, Rr."Oksana Budina" No. 4, Tirana 007, Albania. Phone: 00355682444832. E-Mail: rama-mirvete@live.com
Received: 04-Apr-2015; Revised: 12-May-2015; Accepted: 13-May-2015; Online first: 28-May-2015
Copyright: © 2015 Mirvete Rama, Mirela Miraci, Idriz Balla, Ela Petrela, Ledjan Malaj, Anjeza Koleci. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Competing Interests: The authors have declared that no competing interests exist.
 

Full text (pdf)

Full text OnlineFirst (pdf)